Stocks Health care MRKR
NASDAQ · Health careMarker Therapeutics, Inc. (MRKR)
It posted a net loss of $8.7M. At June 30, 2026 it held $11.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Marker Therapeutics, Inc.
- Net worth
- Marker Therapeutics, Inc. has a market value (market cap) of $15.7M at the latest share price, and shareholders' equity of $12.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $3.5M (-46.2% year on year), with a net loss of $12.2M.
- Cash flow
- In fiscal 2025 operations used $12M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Marker Therapeutics, Inc. does
Marker Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MRKR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3.5M | -$12.2M | -$0.79 | n/a |
| 2024 | $6.6M | -$10.7M | -$1.19 | n/a |
| 2023 | $3.3M | -$8.2M | -$0.94 | n/a |
| 2022 | $3.5M | -$29.9M | -$3.58 | n/a |
| 2021 | $1.2M | -$41.9M | -$5.47 | n/a |
| 2020 | $500K | -$28.7M | -$6.07 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MRKR ranks in Health care
Latest SEC filings
What Marker Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 115% to $751.7K versus the same quarter last year; diluted EPS -$0.16 versus -$0.40.
- May 4, 2026
- March 20, 2026Additional proxy material DEFA14A
- March 20, 2026
- March 20, 2026Proxy statement DEF 14A
- March 19, 2026
- March 18, 2026Annual report 10-K · period to December 31, 2025Revenue fell 46% to $3.5M versus the prior year; diluted EPS -$0.79 versus -$1.19.
- March 10, 2026Preliminary proxy statement PRE 14A
- February 9, 2026
Insider trades
What the people running Marker Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns MRKR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Blue Owl Capital Holdings LP13G, passive | 9.99% | May 15, 2025 |
| Alyeska Investment Group, L.P.13G, passive with 2 related filers | 9.9% | November 14, 2025 |
| New Enterprise Associates 16, L.P.13D, may seek influence with 9 related filers | 9.9% | November 17, 2025 |
Largest institutional holders
Insiders
Questions about MRKR
What does Marker Therapeutics, Inc. do?
Marker Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as MRKR. Its shares trade on NASDAQ under the ticker MRKR.
What is Marker Therapeutics, Inc.'s net worth?
Marker Therapeutics, Inc. has a market value (market cap) of $15.7M at the latest share price, and shareholders' equity of $12.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Marker Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $8.7M.
When did Marker Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.
Similar companies
Compare MRKR with
Follow MRKR
Get an email when Marker Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Marker Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.